Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Aug 21, 2014 (12 years ago)

Candesartan Cilexetil and Hydrochlorothiazide Tablets 32 mg/12.5 mg

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed Impurity/Degradation Specification; high out of specification for CAD II degradant

Cause type: Impurity / degradation

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present. All impurity / degradation recalls.

What was recalled

Candesartan Cilexetil and Hydrochlorothiazide Tablets 32 mg/12.5 mg, 90 count bottles, Rx only, Manufactured by: Apotex Research Pvt. Ltd. Bangalore - 560 099, India NDC 60505-3759-9

Affected NDC 60505-3759-09

Compare with the code on your package — it is the most precise check available.

Drug: Hydrochlorothiazide Category: Blood Pressure Medication

Recalling firm
Apotex Corp.
NDC code
60505-3759-9
Origin
FL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1570-2014 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Hydrochlorothiazide recalls

See all
Class II · Moderate risk

Lisinopril and Hydrochlorothiazide Tablets USP 20mg/12.5mg

Product Mix Up: This product is being recalled because of a complaint received that a sealed bottle of lisinopril and hydrochlorothiazide tablets 20mg/12.5 mg had a foreign tablet identified as atazanavir and ritonavir tablet 300mg/100mg.

Ongoing Labeling / mix-up Lupin Pharmaceuticals Inc. NDC 68180-519-01 D-0532-2025

Other recalls by Apotex Corp.

All 2014 recalls
Class II · Moderate risk

Paxil CR

Failed Dissolution Specifications; product failed to meet 24-month stability testing acceptance criteria

Ongoing Dissolution failure Apotex Corp. NDC 60505-4379-3 D-0804-2026
Class II · Moderate risk

Desmopressin Nasal Spray

Defective container: defect in a batch of bottle caps, specifically involving dislodged or missing cap liners.

Ongoing Packaging defect Apotex Corp. NDC 60505-0815-0 D-0510-2026